Our mission is to identify novel drug targets and effective therapeutics for fibrosis and solid tumours by testing cells in their natural microenvironment using our pioneering human extracellular matrix platform.
A new model for drug discovery
We are developing a portfolio of programmes in fibrosis and solid tumours using our proprietary human extracellular matrix (ECM)-based discovery platform. The use of physiologically realistic human in vitro models is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates.
Transatlantic biotechnology company
Engitix is headquartered at the Royal Free Hospital, London, at the centre of the UK’s renowned healthcare network, with its wholly-owned US subsidiary, Engitix, Inc, based at LabCentral’s research facility in Cambridge, Massachusetts, USA.
“Engitix is developing a unique platform with many applications, which allows the study of human pathophysiology leading to the discovery of novel targets and therapeutics that will benefit patients through the acceleration of drug discovery in liver disease and cancer.”
Steve Arlington, PhD, Chairman
Our vision is to create a healthier future for patients with life-threatening diseases such as fibrosis and cancer.
